![]()
CARDIO: Heart Failure - PROACTIVE-HF TRIAL
Dr. Jason Gluck is participating in this trial collecting information which will provide clinicians with a better understanding of the Cordella PA Sensor System as a potential solution for proactive Heart Failure management, early detection of fluid overload and possibly the prevention of worsening Heart Failure symptoms.
![]()
CARDIO: Heart Failure - DAPA TIMI 68
Dr. Jaiswal and Hartford Hospital’s Heart Failure Department are enrolling patients in this international trial for patients with heart failure and reduced ejection fraction who will be randomized to dapagliflozin versus placebo while in the hospital.
![]()
CARDIO: Electrophysiology - LEADR
Dr. Meir Friedman is the Principal Investigator for this trial. The Next Generation ICD Lead is indicated for the treatment of subjects who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias. The purpose of this study is to assess the safety and efficacy of the Next Generation ICD Lead.
CARDIO: Electrophysiology - VANISH-2
Under the direction of Eric Crespo, MD and the Electrophysiology Department, this study will determine whether catheter ablation or antiarrhythmic drug therapy provides the most effective control of important clinical outcomes for patients with prior myocardial infarction and sustained monomorphic ventricular tachycardia.
![]()
CARDIO: Electrophysiology - The Arm Aflutter Study
Dr. Aneesh Tolat is the Principal Investigator for this trial evaluating the safety, feasibility, and efficacy of performing typical atrial flutter ablation through the arm.
CARDIO: Structural - APOLLO
Dr. Talhat Azemi in conjunction with the Structural Heart Team are participating in this international trial evaluating the safety and efficacy of the Medtronic Intrepid TMVR system in patients with moderate to severe or severe symptomatic mitral regurgitation who are unable to have standard transcatheter or surgical repair.
![]()
CARDIO: Vascular - SSB 11-02
The primary objective of the study is to determine whether the GORE® TAG® Thoracic Branch Endoprosthesis (TBE device) is safe and effective in treating thoracic aortic pathologies.
![]()
CARDIO: Vascular - CREST-2
Dr. Parth Shah and the Vascular Surgery Team will be participating in this two-parallel multi-centered, randomized, observer-blinded endpoint clinical trial. One trial will assess treatment differences between intensive medical management alone compared to carotid endarterectomy with intensive medical management. The parallel trial will assess treatment differences between intensive medical management alone compared to carotid artery stenting plus intensive medical management.
![]()
CARDIO: Vascular - CREST-H
Dr. Shah in conjunction with the Vascular Surgical team will participate in this trial to determine whether patients with cerebral hemodynamic impairment and mild cognitive impairment benefit from carotid revascularization.
![]()
CARDIO: Cardiac Surgery - ON-X Post Approval Clinical Registry Study
Dr. Robert Hagberg and the Cardiac Surgical Team will evaluate the On-X aortic valve performance in normal general open practice using a new lower anticoagulant (blood thinner) dose approved and recommended by the United States Food and Drug Administration (FDA) in 2015.
![]()
CARDIO: Cardiac Surgery - PERIGON
The purpose of this trial is to evaluate the safety and effectiveness of the Medtronic Model 400 aortic valve bioprosthesis in a patient undergoing surgical aortic valve replacement of a native aortic valve, or replacement of a failed prosthesis.
![]()
CARDIO: Cardiac Catheterization - STEMI DTU
This trial hopes to demonstrate that left ventricular unloading with Impella and a 30 minute delay to reperfusion when compared with immediate PCI will show a reduction in infarct size and heart failure related clinical events.
![]()
CARDIO: Cardiac Catheterization - Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
People who have had a heart attack can have another heart attack and stroke in the future. The test being researched is a blood test that is designed to guide personalized treatment designed to prevent those events.
![]()
CARDIO: Preventive Cardiology - The Horizon Study
The Horizon Study is a randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with known cardiovascular disease.
CARDIO: Preventive Cardiology - The CASCADE FH Registry
CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia is being conducted under the direction of Dr. Paul Thompson and Preventive Cardiology.
CARDIO: Preventive Cardiology (iSCAD)
The aim of the International SCAD (iSCAD) Registry is to serve as an internationally collaborative, multicenter registry coordinated by an experienced, centralized, coordinating center in an effort to increase the pace of patient recruitment and thereby increase statistical power of studies related to SCAD. This observational iSCAD Registry is being conducted under the direction of Dr. Stephanie Saucier and Preventive Cardiology.
CARDIO: Vascular Surgery C2LOE
Dr. Parth Shah and the Vascular Surgery Team will be participating in the Long-Term Observational Extension of Participants in the CREST-2 (C2LOE) Randomized Clinical Trial study. The purpose of C2LOE is to assess post-procedural efficacy of carotid endarterectomy and carotid stenting.
CARDIO: Heart Failure - Integra-D
The purpose of this study is to evaluate the device effectiveness in converting induced VF at the time of implantation.
CARDIO: Heart Failure - Aim Higher
The purpose of this study is to determine whether CCM® treatment will reduce the occurrence of cardiovascular mortality and heart failure hospitalizations in patients with less severe heart failure.
CARDIO: Ventricular Tachycardia (RADIATE-VT Trial)
The RADIATE-VT trial (NCT 05765175) is the first international, multi-center, randomized controlled trial to evaluate the safety and efficacy of cardiac radioablation (CRA) with Varian's CRA system compared to repeat catheter ablation for patients with high-risk refractory ventricular tachycardia (VT).